Kazimierz Wisniewski Selected Research

FE 201874

9/2013

Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazimierz Wisniewski Research Topics

Disease

4	Septic Shock (Toxic Shock Syndrome) 09/2013 - 06/2011
2	Hypotension (Low Blood Pressure) 07/2011 - 06/2011
1	Migraine Disorders (Migraine) 01/2022

Drug/Important Bio-Agent (IBA)

3	Phe(2)-Ile(3)-Hgn(4)-Orn(iPr)(8)- vasopressinIBA 06/2012 - 06/2011
2	Arginine Vasopressin (Argipressin)IBA 09/2013 - 06/2012
2	Vasopressins (Vasopressin)IBA 06/2012 - 07/2011
2	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 06/2012 - 06/2011
1	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	NeuropeptidesIBA 01/2022
1	Calcitonin Gene-Related PeptideIBA 01/2022
1	Vasodilator Agents (Vasodilators)IBA 09/2013
1	Oxytocin (Pitocin)FDA LinkGeneric 09/2013
1	FE 201874IBA 09/2013
1	von Willebrand FactorIBA 06/2012
1	Blood Coagulation Factors (Coagulation Factor)IBA 07/2011

Therapy/Procedure

1	Injections 01/2022
1	Therapeutics 01/2022
1	Controlled Hypotension 09/2013